Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Chemomab Therapeutics Ltd. - American Depositary Shares (NQ:CMMB)

1.920 +0.110 (+6.08%)
Streaming Delayed Price Updated: 12:34 PM EST, Jan 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Chemomab Therapeutics Ltd. - American Depositary Shares

< Previous 1 2 3 4 5 6 Next >
News headline image
Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
 
Via Benzinga
News headline image
Chemomab Therapeutics to Present at September 2024 Investor Conferences
From Chemomab Therapeutics
Via GlobeNewswire
News headline image
CMMB Stock Earnings: Chemomab Therapeutics Reported Results for Q2 2024 ↗
Chemomab Therapeutics just reported results for the second quarter of 2024. 
Via InvestorPlace
News headline image
Chemomab Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update
From Chemomab Therapeutics
Via GlobeNewswire
News headline image
Chemomab Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update
From Chemomab Therapeutics
Via GlobeNewswire
News headline image
Chemomab Therapeutics Announces Closing of $10 Million Private Placement
From Chemomab Therapeutics
Via GlobeNewswire
News headline image
Chemomab Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement
From Chemomab Therapeutics
Via GlobeNewswire
News headline image
Chemomab Therapeutics Reveals Data From Mid-Stage Study For Liver Disease Candidate, Stock Plunges On Capital Raise ↗
Chemomab Therapeutics reports successful Phase 2 SPRING trial results for CM-101 in primary sclerosing cholangitis, showing safety and efficacy. Key findings include significant improvements in liver... 
Via Benzinga
News headline image
Chemomab Therapeutics Announces $10 Million Private Placement
From Chemomab Therapeutics
Via GlobeNewswire
News headline image
Chemomab Therapeutics Announces Positive Phase 2 Trial Results: CM-101 Achieves Primary and Secondary Endpoints Demonstrating Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Effects in Patients with Primary Sclerosing Cholangitis
From Chemomab Therapeutics
Via GlobeNewswire
News headline image
Chemomab Therapeutics Announces New Publications Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis
From Chemomab Therapeutics
Via GlobeNewswire
News headline image
Chemomab Therapeutics Presents Data Supporting the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2024 and a Gordon Research Conference
From Chemomab Therapeutics
Via GlobeNewswire
News headline image
Chemomab Therapeutics to Participate in Upcoming Scientific Conferences
From Chemomab Therapeutics
Via GlobeNewswire
News headline image
CMMB Stock Earnings: Chemomab Therapeutics Reported Results for Q1 2024 ↗
Chemomab Therapeutics just reported results for the first quarter of 2024. 
Via InvestorPlace
News headline image
Chemomab Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
From Chemomab Therapeutics
Via GlobeNewswire
News headline image
Chemomab Therapeutics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule
From Chemomab Therapeutics
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
Chemomab Therapeutics to Present at 2024 Aegis Virtual Conference
From Chemomab Therapeutics
Via GlobeNewswire
News headline image
Chemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update
From Chemomab Therapeutics
Via GlobeNewswire
News headline image
Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis
From Chemomab Therapeutics
Via GlobeNewswire
News headline image
Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024
From Chemomab Therapeutics
Via GlobeNewswire
News headline image
Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis
From Chemomab Therapeutics
Via GlobeNewswire
News headline image
CMMB Stock Earnings: Chemomab Therapeutics Reported Results for Q4 2023 ↗
Chemomab Therapeutics just reported results for the fourth quarter of 2023. 
Via InvestorPlace
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Earnings Scheduled For March 7, 2024 ↗
Companies Reporting Before The Bell • CI&T (NYSE:CINT) is estimated to report quarterly earnings at $0.06 per share on revenue of $106.08 million. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
What's Going On With Fibro-Inflammatory Disease Focused Chemomab Therapeutics On Tuesday? ↗
Chemomab Therapeutics' CM-101 granted new patents in Brazil and Israel, currently in Phase 2 SPRING trial for primary sclerosing cholangitis. Topline data readout expected by mid-2024. 
Via Benzinga
Topics Intellectual Property
News headline image
Why M.D.C. Holdings Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket ↗
Shares of M.D.C. Holdings, Inc. (NYSE: MDC) rose sharply in today’s pre-market trading. Sekisui House, Ltd. and M.D.C. Holdings announced an agreement pursuant to which a wholly-owned subsidiary of... 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗
Pre-market stock movers are a hot topic this morning as we check out all of the winners and losers worth keeping tabs on for Thursday! 
Via InvestorPlace
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.